MDMB-BINACA

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

MDMB-BINACA
Identifiers
  • methyl (2S)-2-[(1-butylindazole-3-carbonyl)amino]-3,3-dimethylbutanoate
PubChem CID
ChemSpider
UNII
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H27N3O3
Molar mass345.443 g·mol−1
3D model (JSmol)
  • CCCCN1C2=CC=CC=C2C(=N1)C(=O)N[C@H](C(=O)OC)C(C)(C)C
  • InChI=1S/C19H27N3O3/c1-6-7-12-22-14-11-9-8-10-13(14)15(21-22)17(23)20-16(18(24)25-5)19(2,3)4/h8-11,16H,6-7,12H2,1-5H3,(H,20,23)/t16-/m1/s1
  • Key:YHAWFWPNIXPRDT-MRXNPFEDSA-N

MDMB-BINACA (MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. It has a similar chemical structure to potent cannabinoid agonists previously reported such as ADB-BUTINACA and MDMB-5'Br-BUTINACA, and is believed to have similar effects.[1]

See also

[edit | edit source]

References

[edit | edit source]
  1. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).


Stub icon

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "http://70.231.62.181/index.php?title=MDMB-BINACA&oldid=23937759"